Water Vapor Ablation for Prostate Cancer: Long-Term Registry
Part of paid clinical trials in San Antonio, Texas.
- Sponsor
- Francis Medical Inc.
- Study ID
- NCT07455058
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Vanquish Therapy — DEVICEThe Francis Medical, Inc. Vanquish Water Vapor Ablation Device ("Vanquish" or "Vanquish System") is a transurethral thermal water vapor ablation device. The Vanquish System is designed ablate prostate tissue, while minimizing side effects.
Study Details
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
Key Dates
- Start date
- Jun 5, 2026
- Status verified
- Feb 2026
- Primary completion
- Apr 30, 2041
- Completion
- Jul 31, 2041
Study Design
- Enrollment
- 2,500 participants (estimated)
Arms
- Arm: Vanquish Procedure PatientsPatients that have completed or will complete a Vanquish therapy and plan to continue their routine clinical care.
Primary Outcome Measure
Primary Efficacy Outcome [ Time Frame: Through study completion, or up to 15 years. ]
Central Contacts
- Sydney Cartie6122866855
- Garrett Grenier763-453-9404
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The Urology Place, Inc. | San Antonio | Texas | 78240 | Naveen Kella, MD (PRINCIPAL_INVESTIGATOR) Savannah Eggerss, PA (SUB_INVESTIGATOR) |
| Urology of Virginia | Virginia Beach | Virginia | 23462 | Robert Given, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Antonio, TX
By condition
By specialty
Related Studies
- Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical ProstatectomyRecruiting · Proton Collaborative Group · Little Rock, Arkansas
- Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate CancerPHASE3 · Recruiting · Proton Collaborative Group · Scottsdale, Arizona
- Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical ProstatectomyPHASE3 · Recruiting · yair lotan · Dallas, Texas
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyPHASE2 · Recruiting · Astellas Pharma Global Development, Inc. · Anchorage, Alaska